Urhie Ogaga, Turner Ryan, Lucke-Wold Brandon, Radwan Walid, Ahn Janice, Gyure Kymberly, Bhatia Sanjay
West Virginia University School of Medicine, Morgantown, West Virginia, USA; Department of Neurosurgery, West Virginia University Hospitals, Morgantown, West Virginia, USA.
Department of Neurosurgery, West Virginia University Hospitals, Morgantown, West Virginia, USA.
World Neurosurg. 2018 Jul;115:e59-e66. doi: 10.1016/j.wneu.2018.03.163. Epub 2018 Apr 6.
Glioblastoma is a fatal brain cancer with low median and yearly survival rates. Standard of care for treating glioblastoma is gross total resection (GTR) coupled with the Stupp protocol, but various factors influence the interventions undertaken and survival achieved. As health disparities exist in rural areas, survival in these areas needs to be assessed to understand which factors detract from the successes of these standard medical interventions.
We retrospectively determined impact of age at diagnosis, number of lesions, the molecular marker O-methylguanine methyltransferase (MGMT), extent of surgery, and completion of the Stupp protocol on survival in patients treated at West Virginia University Hospitals. We also compared our findings with a pre-Stupp protocol study done in West Virginia in 1996.
Age <60 years at diagnosis, having the MGMT gene methylated, having a unifocal tumor, receiving GTR, adhering to the Stupp protocol, and undergoing a treatment course of GTR followed by the Stupp protocol significantly increased survival. Comparison with the 1996 study showed that although overall median survival has not increased, all interventions involving GTR have resulted in a significantly higher survival.
We can serve our patient population by offering GTR to all adult patients with glioblastoma when no contraindications exist and ensuring that patients follow the Stupp protocol. After discharge, the Stupp protocol may not be followed or completed for a variety of reasons. In the future, we aim to assess these reasons and analyze other significant interventional and socioeconomic factors that influence survival.
胶质母细胞瘤是一种致命的脑癌,中位生存期和年生存率较低。治疗胶质母细胞瘤的标准治疗方案是大体全切术(GTR)联合施图普方案,但多种因素会影响所采取的干预措施和生存情况。由于农村地区存在健康差异,需要评估这些地区的生存率,以了解哪些因素会影响这些标准医疗干预措施的成效。
我们回顾性地确定了诊断时的年龄、病灶数量、分子标志物O-甲基鸟嘌呤甲基转移酶(MGMT)、手术范围以及施图普方案的完成情况对在西弗吉尼亚大学医院接受治疗的患者生存情况的影响。我们还将我们的研究结果与1996年在西弗吉尼亚进行的一项施图普方案前的研究进行了比较。
诊断时年龄<60岁、MGMT基因甲基化、肿瘤为单灶性、接受大体全切术、坚持施图普方案以及接受先进行大体全切术然后实施施图普方案的治疗过程,均显著提高了生存率。与1996年的研究相比,虽然总体中位生存期没有增加,但所有涉及大体全切术的干预措施都使生存率显著提高。
当不存在禁忌证时,我们可以通过为所有成年胶质母细胞瘤患者提供大体全切术并确保患者遵循施图普方案来为我们的患者群体提供服务。出院后,由于各种原因,施图普方案可能无法遵循或完成。未来,我们旨在评估这些原因,并分析其他影响生存的重要干预因素和社会经济因素。